Valentina Corigliano, Anna Comparelli, Iginia Mancinelli, Benedetta Montalbani, Dorian A Lamis, Antonella De Carolis, Denise Erbuto, Paolo Girardi, Maurizio Pompili
{"title":"长效注射第二代抗精神病药物改善新近诊断的精神分裂症患者的阴性症状和自杀意念:一项为期1年的随访试点研究","authors":"Valentina Corigliano, Anna Comparelli, Iginia Mancinelli, Benedetta Montalbani, Dorian A Lamis, Antonella De Carolis, Denise Erbuto, Paolo Girardi, Maurizio Pompili","doi":"10.1155/2018/4834135","DOIUrl":null,"url":null,"abstract":"Long-acting injectable second-generation antipsychotics (LAI-SGA) are typically used to maintain treatment adherence in patients with chronic schizophrenia. Recent research suggests that they may also provide an effective treatment strategy for patients with early-phase disease. The aim of this study is to evaluate clinical and psychosocial outcomes among recent and long-term diagnosed schizophrenia outpatients treated with LAI-SGA during a follow-up period of 12 months. Stable schizophrenia patients receiving LAI-SGA with 5 or less years of illness duration (n = 10) were compared to those with more than 5 years of illness duration (n = 15). Clinical data was assessed through the Positive and Negative Syndrome Scale (PANSS), the Global Assessment of Functioning (GAF), the Columbia Suicide Severity Rating Scale (C-SSRS), the Recovery Style Questionnaire (RSQ), and the Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT) Managing Emotion branch. Recently diagnosed patients showed greater improvement versus patients diagnosed for more than 5 years in adjusted mean GAF score, in PANSS factor score for negative and depressive symptoms, and in severity and intensity of suicidal ideation. Our preliminary findings support the hypothesis that LAI-SGA may influence the course of the illness if administered at the early phase of the illness. However, replicate studies are needed, possibly with larger samples.","PeriodicalId":45388,"journal":{"name":"Schizophrenia Research and Treatment","volume":"2018 ","pages":"4834135"},"PeriodicalIF":3.6000,"publicationDate":"2018-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2018/4834135","citationCount":"19","resultStr":"{\"title\":\"Long-Acting Injectable Second-Generation Antipsychotics Improve Negative Symptoms and Suicidal Ideation in Recent Diagnosed Schizophrenia Patients: A 1-Year Follow-up Pilot Study.\",\"authors\":\"Valentina Corigliano, Anna Comparelli, Iginia Mancinelli, Benedetta Montalbani, Dorian A Lamis, Antonella De Carolis, Denise Erbuto, Paolo Girardi, Maurizio Pompili\",\"doi\":\"10.1155/2018/4834135\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Long-acting injectable second-generation antipsychotics (LAI-SGA) are typically used to maintain treatment adherence in patients with chronic schizophrenia. Recent research suggests that they may also provide an effective treatment strategy for patients with early-phase disease. The aim of this study is to evaluate clinical and psychosocial outcomes among recent and long-term diagnosed schizophrenia outpatients treated with LAI-SGA during a follow-up period of 12 months. Stable schizophrenia patients receiving LAI-SGA with 5 or less years of illness duration (n = 10) were compared to those with more than 5 years of illness duration (n = 15). Clinical data was assessed through the Positive and Negative Syndrome Scale (PANSS), the Global Assessment of Functioning (GAF), the Columbia Suicide Severity Rating Scale (C-SSRS), the Recovery Style Questionnaire (RSQ), and the Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT) Managing Emotion branch. Recently diagnosed patients showed greater improvement versus patients diagnosed for more than 5 years in adjusted mean GAF score, in PANSS factor score for negative and depressive symptoms, and in severity and intensity of suicidal ideation. Our preliminary findings support the hypothesis that LAI-SGA may influence the course of the illness if administered at the early phase of the illness. However, replicate studies are needed, possibly with larger samples.\",\"PeriodicalId\":45388,\"journal\":{\"name\":\"Schizophrenia Research and Treatment\",\"volume\":\"2018 \",\"pages\":\"4834135\"},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2018-08-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1155/2018/4834135\",\"citationCount\":\"19\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Schizophrenia Research and Treatment\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/2018/4834135\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2018/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Schizophrenia Research and Treatment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2018/4834135","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 19
摘要
长效注射第二代抗精神病药物(LAI-SGA)通常用于维持慢性精神分裂症患者的治疗依从性。最近的研究表明,它们也可能为早期疾病患者提供一种有效的治疗策略。本研究的目的是在12个月的随访期间评估近期和长期诊断为精神分裂症的门诊患者接受LAI-SGA治疗的临床和社会心理结果。接受LAI-SGA治疗的病程不超过5年的稳定精神分裂症患者(n = 10)与病程超过5年的患者(n = 15)进行比较。临床资料采用Positive and Negative Syndrome Scale (PANSS)、Global Assessment of Functioning (GAF)、Columbia自杀严重程度评定量表(C-SSRS)、康复风格问卷(RSQ)和Mayer-Salovey-Caruso情绪智力测验(MSCEIT)情绪管理分支进行评估。与确诊时间超过5年的患者相比,最近确诊的患者在GAF校正平均评分、阴性和抑郁症状的PANSS因子评分以及自杀意念的严重程度和强度方面均有更大的改善。我们的初步研究结果支持这样的假设,即如果在疾病的早期阶段给予li - sga,可能会影响疾病的病程。然而,可能需要更大样本的重复研究。
Long-Acting Injectable Second-Generation Antipsychotics Improve Negative Symptoms and Suicidal Ideation in Recent Diagnosed Schizophrenia Patients: A 1-Year Follow-up Pilot Study.
Long-acting injectable second-generation antipsychotics (LAI-SGA) are typically used to maintain treatment adherence in patients with chronic schizophrenia. Recent research suggests that they may also provide an effective treatment strategy for patients with early-phase disease. The aim of this study is to evaluate clinical and psychosocial outcomes among recent and long-term diagnosed schizophrenia outpatients treated with LAI-SGA during a follow-up period of 12 months. Stable schizophrenia patients receiving LAI-SGA with 5 or less years of illness duration (n = 10) were compared to those with more than 5 years of illness duration (n = 15). Clinical data was assessed through the Positive and Negative Syndrome Scale (PANSS), the Global Assessment of Functioning (GAF), the Columbia Suicide Severity Rating Scale (C-SSRS), the Recovery Style Questionnaire (RSQ), and the Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT) Managing Emotion branch. Recently diagnosed patients showed greater improvement versus patients diagnosed for more than 5 years in adjusted mean GAF score, in PANSS factor score for negative and depressive symptoms, and in severity and intensity of suicidal ideation. Our preliminary findings support the hypothesis that LAI-SGA may influence the course of the illness if administered at the early phase of the illness. However, replicate studies are needed, possibly with larger samples.
期刊介绍:
Schizophrenia Research and Treatment is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies related to all aspects of schizophrenia.